Chemotherapy Induced Neutropenia - Pipeline Insight, 2024

This “Chemotherapy Induced Neutropenia - Pipeline Insight, 2024,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Chemotherapy Induced Neutropenia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Chemotherapy Induced Neutropenia Understanding

Chemotherapy Induced Neutropenia: Overview

Chemotherapy-induced neutropenia (CIN) is one of the most common side effects seen in cancer patients. As an adverse event, it is deemed undesirable since it often constitutes a dose-limiting toxicity for cytotoxic agents leading to treatment delays and/or dose reductions. It is also associated with a financial cost component from diagnostic work-up and treatment of patients with chemotherapy-induced febrile neutropenia (CIFN). Neutropenia is commonly accompanied by a decrease in other hematopoietic lineages (anemia and/or thrombocytopenia). Dosing of chemotherapeutic agents is based on the severity of adverse effects seen. Depending on the degree of neutropenia, chemotherapeutic agents may be put on hold until count recovery and growth factor support might be added to allow for dosing as scheduled. However, neutropenia appears to be more than just an adverse event. While CIFN by itself constitutes an adverse event, the appearance of just CIN is not necessarily a marker of poor outcome. In fact, it rather appears to be a surrogate marker of response and/or survival in patients treated with cytotoxic regimens.

Chemotherapy Induced Neutropenia - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chemotherapy Induced Neutropenia pipeline landscape is provided which includes the disease overview and Chemotherapy Induced Neutropenia treatment guidelines. The assessment part of the report embraces, in depth Chemotherapy Induced Neutropenia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chemotherapy Induced Neutropenia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Chemotherapy Induced Neutropenia.
• In the coming years, the Chemotherapy Induced Neutropenia market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies and academics that are working to assess challenges and seek opportunities that could influence Chemotherapy Induced Neutropenia R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.

• A detailed portfolio of major pharma players who are involved in fueling the Chemotherapy Induced Neutropenia treatment market. Several potential therapies for Chemotherapy Induced Neutropenia are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Chemotherapy Induced Neutropenia market size in the coming years.
• This in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Chemotherapy Induced Neutropenia) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Chemotherapy Induced Neutropenia Emerging Drugs Chapters

This segment of the Chemotherapy Induced Neutropenia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Chemotherapy Induced Neutropenia Emerging Drugs

ALRN-6924: Aileron ALRN-6924 is a novel medicine designed to selectively protect healthy cells in patients with cancers that harbor p53 mutations to reduce or eliminate chemotherapy-induced side effects without interrupting chemotherapy’s destruction of cancercells.

EC-18: Enzychem Lifesciences EC-18 was developed over two decades of research by Drs. Changgi D. Hong and Sang-Hee Kim at Asan Medical Center in Seoul. EC-18 is Enzychem’s leading compound, which is a proprietary compound originally derived from Sika deer antler. After the initial research on this unique compound, Enzychem Lifesciences conducted an additional six years of research on EC-18 to fully synthesize the compound and to be equipped with mass production capability. Based on our findings from preclinical and clinical studies, Enzychem Lifesciences is developing EC-18 for indications including chemoradiation induced oral mucositis (CRIOM), chemotherapy induced neutropenia (CIN), acute radiation syndrome (ARS), acute respiratory distress syndrome associated with COVID-19, Immune Checkpoint Inhibitors (ICI), and Non-alcoholic Steatohepatitis(NASH).

Chemotherapy Induced Neutropenia: Therapeutic Assessment

This segment of the report provides insights about the different Chemotherapy Induced Neutropenia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Chemotherapy Induced Neutropenia

There are approx. 3+ key companies which are developing the therapies for Chemotherapy Induced Neutropenia. The companies which have their Chemotherapy Induced Neutropenia drug candidates in the most advanced stage, i.e. phase II include, Enzychem Lifesciences.

Phases

This report covers around 3+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Chemotherapy Induced Neutropenia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Chemotherapy Induced Neutropenia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chemotherapy Induced Neutropenia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chemotherapy Induced Neutropenia drugs.

Chemotherapy Induced Neutropenia Report Insights

• Chemotherapy Induced Neutropenia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Chemotherapy Induced Neutropenia Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Chemotherapy Induced Neutropenia drugs?
• How many Chemotherapy Induced Neutropenia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chemotherapy Induced Neutropenia?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Chemotherapy Induced Neutropenia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Chemotherapy Induced Neutropenia and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Aileron
• Enzychem Lifesciences
• Myelo Therapeutics GmbH
• Beyond SpringInc.

Key Products

• ALRN-6924
• EC-18
• myelo001
• Plinabulin